Respiratory Syncytial Virus Prophylaxis: Eight-Market Drug Forecast and Market Analysis - Update

The report provides an in-depth assessment of the RSV prophylaxis market including disease overview, epidemiology, disease management, current treatment options, unmet needs and opportunities, R&D strategies, pipeline assessment, current and future players, and market outlook.

Human respiratory syncytial virus (RSV) is an enveloped, single-stranded, negative-sense RNA orthopneumovirus belonging to the family of Pneumoviridae. The virus was discovered in 1956, first as an isolate from a laboratory chimpanzee displaying symptoms of the common cold, and later from infants suffering from respiratory disease (Chanock et al., 1957). The most common clinical scenario for RSV is an upper respiratory tract infection that is typically mild and self-limiting. However, RSV is the leading cause of lower respiratory tract infections (LRTIs) in infants, with a peak age of hospitalization between 2-3 months of age. Severe respiratory disease can manifest as bronchiolitis and pneumonia, which can progress to respiratory failure or death in rare occasions (Borchers et al., 2013). RSV is also an important cause of hospitalizations and deaths in elderly adults (Walsh et al., 2012).

Up until recently, there was only one marketed pharmaceutical product indicated for the prevention of RSV infections. AstraZeneca/AbbVie's Synagis (palivizumab), a prophylactic, humanized, mouse monoclonal antibody (mAb), has been indicated for the prophylaxis of RSV in infants at a high risk of severe infection since 1998. Synagis is licensed in all of the 8MM and has been shown to be effective for preventing severe RSV infection in infants and children with prematurity, bronchopulmonary dysplasia (BPD), and congenital heart defects (CHD). However, the 20-day half-life of Synagis, requirement for monthly dosing during the RSV season, and prohibitively high cost has led to its decreased use over time. Significant strides have been made in the RSV space in recent years with the approval of four new prophylactic products. Sanofi's Beyfortus (nirsevimab) is a human recombinant mAb used for the prevention of RSV lower respiratory tract disease (LRTD) in neonates and infants during their first RSV season, and children up to 24 months of age who are considered vulnerable to severe RSV disease during their second RSV season. It has been marketed in all 8MM. Pfizer's Abrysvo is a bivalent vaccine composed of two recombinant RSV fusion surface glycoproteins selected to optimize protection against RSV A and B strains. It is indicated for the prevention of LRTD caused by RSV in both adults aged 60 or older, as well as in infants from birth up to six months of age by active immunization of pregnant individuals in all 8MM. The FDA has just approved Abrysvo for use in adults aged 18-59 at an increased risk of infection too, and the other 7MM will likely follow suit shortly. GSK’s Arexvy, an adjuvanted subunit vaccine, has been approved for use in adults aged 60 and older in all 8MM, as well as those between 50-59 years old at an increased risk of infection in the EU and US, for the prevention of LRTD caused by RSV. New positive Phase IIIb data for Arexvy in 18-49-year-olds at high risk of infection shows potential for further label expansion. Moderna's mRESVIA is the first mRNA vaccine to join the market, approved for use in adults aged 60 years and older in the US and EU.

The analyst projects the global RSV marketplace-which, for the purposes of this report, comprises eight major pharmaceutical markets (US, France, Germany, Italy, Spain, UK, Japan, and Australia)-to experience continued growth during the forecast period. The launch of Merck and Co's clesrovimab in the US and EU (2025), Australia (2026) and Japan (2027) will compete with Beyfortus and together they will replace Synagis as the standard-of-care prophylaxis for high-risk infants. SP-0125 is currently in a Phase III clinical trial and is expected to launch in 2027, being the first pediatric vaccine to reach the market. The recent approval of several therapies for adult, maternal, and pediatric use, such as Pfizer's Abrysvo, GSK’s Arexvy, Sanofi's Beyfortus, and Moderna's mRESVIA, will fulfill a major unmet need, and will have a significant effect on the overall size of the RSV prophylactics market. The US will dominate the global RSV market throughout the entire 2020-30 forecast period.

Key Highlights

Report deliverables include a Pdf report and an Excel-based forecast model

Forecast includes the 8 major markets (8MM)

Forecast covers the period 2020-2030

Scope

• Overview of RSV including etiology, pathophysiology and epidemiology.
• Key topics covered include current market landscape, strategic competitor assessment, unmet needs and opportunities, R&D trends, pipeline assessment, and current and future players.
• RSV prophylaxis market outlook from 2020-2030, including annual cost of therapy per patient, and total sales revenues per product for each of the 8MM.

Reasons to Buy

• Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and identify the companies with the most robust pipeline.
• Develop business strategies by understanding the trends shaping and driving the 8MM RSV prophylaxis market.
• Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the 8MM RSV prophylaxis market in the future.
• Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
• Identify emerging players with potentially strong product portfolios and create effective counterstrategies to gain a competitive advantage.
• Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.